$AZTR

Azitra, Inc. (AZTR): Submission of Matters to a Vote of Security Holders

Azitra, Inc. (AZTR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false --12-31 0001701478 0001701478 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of

Original reporting
Published Jun 16, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$AZTR
Neutral
medium confidence
Mentioned
$AZTR
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AZTRNeutralMed
01

Why it matters

Key voted items include increasing authorized common shares, authorizing potential reverse stock splits, ratifying the auditor, and approving NYSE American Guide-compliant issuances related to prior securities purchase agreements.

02

Market read

The shareholder vote outcomes can shift expectations for dilution and share-price mechanics (reverse split optionality), which may drive short-term trading volatility.

03

What to watch

Traders may overreact to the authorized-share headline; the actual near-term dilution depends on whether and when the company draws on the securities purchase agreement and converts/exercises instruments.

Relevance 6/10Novelty 6/10Timing: Filed June 16, 2026 (event June 15 reconvened annual meeting)

Background

This is an SEC Form 8-K reporting results of Azitra’s reconvened 2026 annual meeting (initially adjourned June 4, 2026).

Company-level read

Ticker impact

$AZTRNeutralMedium confidence
Context

Azitra reconvened its 2026 annual meeting and stockholders approved a large authorized-share increase and other capital-structure proposals.

Expected impact

Choppy-to-negative bias possible if traders focus on dilution risk; reverse-split authorization may add uncertainty.

Evidence & confidence

The filing discloses shareholder votes approving (1) authorized common shares from 200M to 750M, (2) authorization for one or more reverse stock splits, and (3) NYSE American Guide-compliant issuance approvals tied to a securities purchase agreement—inputs that can change dilution/financing expectations even without immediate pricing details.

Market effects

For small-cap listed issuers, authorized-share increases and reverse-split authorizations can signal readiness for financing/recapitalization, influencing peer sentiment around similar capital structures.

Limited; primarily affects the US-listed micro/small-cap name on NYSE American.

Low; no cross-border deal or macro linkage disclosed.

Counterpoint

The reverse-split authorization and share-authorizations may be procedural to support existing financing terms rather than a fresh, immediate dilution event.

Key entities

  • Azitra, Inc.

    NYSE American-listed company whose stockholders voted on eight proposals, including capital-structure changes.

  • Alumni Capital LP

    Named in securities purchase agreement(s) referenced by the NYSE American Guide-compliant issuance proposals.

  • Grassi & Co., CPAs, P.C.

    Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

Related articles

$AZTRMed

Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates

Azitra, Inc. (NYSE American: AZTR) reported Q2 2026 results for the quarter ended June 30, 2026. R&D was $1.4 million, G&A $2.1 million, and net loss $3.3 million. Cash and cash equivalents were $6.7 million. The company cited preclinical ATR-COSF data, continued Phase 1/2 enrollment for ATR-04 EGFR inhibitor-associated rash, and plans to pause ATR-12 enrollment. Topline ATR-04 data is expected in Q4 2026.

$AZTRMed

Azitra, Inc. (AZTR): Results of Operations and Financial Condition

Azitra, Inc. (AZTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 aztrpressrelease6302026-ex.htm EX-99.1 Document Exhibit 99.1 Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates BRANFORD, Conn. – August 12, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical stage biopharmaceutical compa

$FAMed

First Advantage shares fall 8% after Silver Lake secondary share offering

First Advantage (NASDAQ:FA) shares fell about 8% after Silver Lake-affiliated funds announced a secondary offering of 12.5 million FA shares. Bloomberg reported a marketing range of $22.20 to $23.59 versus Monday’s $23.59 close. The company will not sell shares or receive proceeds. J.P. Morgan is underwriter; a 30-day lock-up applies to the seller, with some shares to limited partners.

$AREMed

Alexandria Real Estate Sets 7.25% Interest Through Feb. 15, 2032

Alexandria Real Estate Equities (NYSE: ARE) priced a $1.0 billion public offering of 7.250% Series A fixed-to-fixed reset rate junior subordinated notes due 2057 at 100% of principal. Interest is 7.250% until Feb. 15, 2032, then resets to the 5-year U.S. Treasury plus 2.889%, with a 7.250% floor. Closing expected around Aug. 21, 2026; proceeds for general corporate purposes.

$AREMedAI 8/10

Alexandria Real Estate Equities, Inc. Announces Pricing of Public Offering of $1,000,000,000 of Series A Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2057

Alexandria Real Estate Equities (NYSE: ARE) priced a $1.0 billion public offering of 7.250% Series A fixed-to-fixed reset rate junior subordinated notes due 2057. Notes were priced at par and pay 7.250% until Feb. 15, 2032, then reset to the 5-year Treasury plus 2.889% with a 7.250% floor. Proceeds will fund general corporate purposes. Closing expected Aug. 21, 2026.

$NROMMed

Noble Romans, Inc.: Noble Roman's Announces Financial Data for the 6 Months ended June 30th and other Related Updates

Noble Roman’s, Inc. (OTCQB:NROM) reported 6-month ended June 30, 2026 revenue of about $8.0M vs $7.8M in 2025, and net income after tax accrual about $311k vs $329k. A $6.9M SOFR+4% loan from Lake Forest Bank & Trust replaced prior debt, creating a one-time $353k write-off. Same-store Craft Pizza & Pub sales fell 0.8%.